Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index
説明
<jats:title>Abstract</jats:title><jats:p><jats:italic>NF2</jats:italic> alteration is the most commonly–found genetic abnormality in meningiomas and is known to initiate events for aggressive-type meningiomas. Whereas the prognosis of meningiomas differs depending on their epigenomic/transcriptomic profile, the effect of <jats:italic>NF2</jats:italic> alteration on the prognosis of benign meningiomas is not fully elucidated. This study aimed to probe the importance of <jats:italic>NF2</jats:italic> alteration in prognosis of WHO grade I meningiomas. A long-term retrospective follow-up (5.3 ± 4.5 years) study involving 281 consecutive WHO grade I meningioma patients was performed. We assessed tumour recurrence in correlation with extent of resection (EOR), histopathological findings, tumour location, and <jats:italic>NF2</jats:italic> alteration. “NF2 meningioma” was defined as meningiomas with presence of <jats:italic>NF2</jats:italic> mutation and/or 22q loss. Overall, NF2 meningioma per se was not a predictor of prognosis in the whole cohort; however, it was a predictor of recurrence in supratentorial meningiomas, together with EOR and Ki-67. In a striking contrast, NF2 meningioma showed a better prognosis than non-NF2 meningioma in infratentorial lesion. Supratentorial NF2 meningiomas had higher Ki-67 and forkhead box protein M1 expression than those of others, possibly explaining the worse prognosis in this subtype. The combination of <jats:italic>NF2</jats:italic> alteration, high Ki-67 and supratentorial location defines subgroup with the worst prognosis among WHO grade I meningiomas. Clinical connotation of <jats:italic>NF2</jats:italic> alteration in terms of prognosis of WHO grade I meningioma differs in an opposite way between supratentorial and infratentorial tumors. Integrated anatomical, histopathological, and genomic classifications will provide the best follow-up schedule and proactive measures.</jats:p>
収録刊行物
-
- Acta Neuropathologica Communications
-
Acta Neuropathologica Communications 10 (1), 76-, 2022-05-15
Springer Science and Business Media LLC
